Renalcellcarcinoma accounts for approximately 2% of all cancers diagnosed in the UK, although it is difficult to treat, with a cure rate of about a third.
Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renalcellcarcinoma.
Hampshire PCT said the National Institute for Health and Clinical Excellence (Nice) currently recommends that Sunitinib is not used for the treatment of advanced and metastatic renalcellcarcinoma (kidney cancer).
On the FDA's Fast Track and in phase III testing is the company's BAY 43-9006, a small molecule RAF kinase and VEGF inhibitor that inhibits tumor growth for patients with metastatic renalcellcarcinoma (advanced kidney cancer).